Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HDAC1 | Q13547 | 19/20 | 0.66 |
| ▸ | HDAC8 | Q9BY41 | 19/20 | 0.66 |
| ▸ | HDAC6 | Q9UBN7 | 18/20 | 0.66 |
| ▸ | MEN1 | O00255 | 1/20 | 0.48 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.48 |
| ▸ | MAPT | P10636 | 1/20 | 0.48 |
| ▸ | HPGD | P15428 | 1/20 | 0.48 |
| ▸ | HTT | P42858 | 1/20 | 0.48 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.48 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8250414 | 0.92 | HDAC1 (0.65) | HDAC1HDAC8HDAC6 | |
| SCHEMBL5565828 | 0.90 | HDAC1 (0.81) | HDAC1HDAC8HDAC6 | |
| SCHEMBL5565825 | 0.90 | HDAC1 (0.81) | HDAC1HDAC8HDAC6 | |
| SCHEMBL8243386 | 0.88 | HDAC1 (0.69) | HDAC1HDAC8HDAC6 | |
| SCHEMBL8252542 | 0.87 | HDAC1 (0.70) | HDAC1HDAC8HDAC6 | |
| SCHEMBL8243394 | 0.86 | HDAC1 (0.58) | HDAC1HDAC8HDAC6ALDH1A1HPGD | |
| SCHEMBL8249455 | 0.85 | HDAC1 (0.81) | HDAC1HDAC8HDAC6 | |
| SCHEMBL8249453 | 0.84 | HDAC1 (0.68) | HDAC1HDAC8HDAC6 | |
| SCHEMBL5565801 | 0.82 | HDAC1 (0.80) | HDAC1HDAC8HDAC6 | |
| SCHEMBL5566420 | 0.82 | HDAC1 (0.80) | HDAC1HDAC8HDAC6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7169801-B2 | Histone deacetylase inhibitors | TAKEDA SAN DIEGO, INC. (US) | 2007-01-30 | — | — | US | disclosed |
| US-20040266769-A1 | Histone deacetylase inhibitors | SYRRX, INC. | 2004-12-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040266769-A1 | Histone deacetylase inhibitors | HDAC1, HDAC11, HDAC10 | HDAC1 1/4885HDAC8 10/4885HDAC6 11/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.